Advanced functionality, accelerated workflow and enhanced hardware control. For more information, click HERE.
Fragment Analyzer is a hands-free, fully automated system that does it all—assessing quality and quantity of DNA, RNA and even genomic DNA up to 40,000 bp.
Next-gen sample QC becomes hassle-free, and you can even build genetic profiles without slab gel for dramatically simplified population and genotyping for SSR and microsatellites.
For more information, click HERE.
MGP Imaging is an independent dental digital imaging company bringing you the best support and advice in the world of X-ray and digital imaging systems.
The company offers a wide choice in X-ray and digital imaging systems from an intra-oral camera to a CBCT scanner, all from big name dental equipment manufactures.
Clients include the NHS, corporate dental companies, dental dealers and manufacturers.
The Rotronic Monitoring System (RMS) checks, documents and visualises all required measurements in one system and makes them available to the user in the desired form. The data can be retrieved from anywhere, at any time by PC, Mac, tablet or smartphone. The system offers the highest level of performance, flexibility, versatility yet is easy to set up and operate. For more information, click HERE. more information HERE.
SpotMap creates a single spot pattern- the spot map - which is applied to all images in the analysis. For more information, click HERE.
Ground-breaking new evidence that cancer spread is increased by a high fat diet as researchers discover new cancer-spreading protein.
The study, published in the journal Nature, identifies for the first time a protein called CD36 which has an essential role in cancer spreading. Finding a way to stop this protein could be a new way to save thousands of lives.
“We expect this study to have a big impact on the scientific community. Things like this don’t happen every day” explains the lead researcher Professor Benitah.
The study shows that the metastatic process (cancer spread) is enhanced by fat intake. During the research mice given a high fat diet, including palmitic acid (a major component of palm oil which is found in lots of household products) developed the most aggressive cancer spread.
A study partly funded by UK charity Worldwide Cancer Research and headed by Professor Salvador Aznar Benitah, at the Institute for Research in Barcelona (IRB) have identified for the first time a specific protein called CD36 on cancer cells which have the ability to metastasize (spread). CD36, found in the cell membranes of tumour cells, is responsible for taking up fatty acids. This unique CD36 activity and dependence on fatty acids distinguishes metastasis-initiating cells from other tumour cells.
Cancer is most deadly when it has begun to spread as successful treatment is much more difficult. Scientists around the globe are therefore trying to understand how the process occurs and develop new ways to stop it.
Professor Benitah’s team found CD36 was present on metastatic cancer cells from patients with a range of different tumours including oral tumours, melanoma skin cancer, ovarian, bladder, lung and breast cancer. To confirm its essential role in cancer spread, they added CD36 to non-metastatic cancer cells which then caused the cells to become metastatic.
“Although we have not yet tested this in all tumour types, we can state that CD36 is a general marker of metastatic cells, the first I know of that is generally specific to metastasis,” says Professor Benitah, Head of the Stem Cell and Cancer Lab at IRB Barcelona. We expect this study to have a big impact on the scientific community and to further advances in metastasis research, and we hope to be able to validate the potential of CD36 as an anti-metastasis treatment. Things like this don’t happen every day.”
The researchers next looked at the role of fat intake on cancer spread. They provided mice with a high fat diet then injected them with a type of human oral cancer. The high fat diet caused 50% more mice to have larger and more frequent metastases.
They went on to test a specific saturated fatty acid called palmitic acid - a major component of animal and vegetable fats and present at high levels in palm oil which is used in many house hold products from peanut butter and processed food to toothpaste. The researchers treated human oral tumours with palmitic acid for two days then injected them into mice fed a standard diet. The team observed that all the mice with CD36 developed cancer spread compared to only half when not treated with palmitic acid.
“In mice inoculated with human tumour cells, there appears to be a direct link between fat intake and an increase in metastatic potential through CD36. More studies are needed to unravel this intriguing relationship, above all because industrialised countries are registering an alarming increase in the consumption of saturated fats and sugar,” warns Professor Benitah. “Fat is necessary for the function of the body, but uncontrolled intake can have an effect on health, as already shown for some tumours such as colon cancer, and in metastasis, as we demonstrate here.”
Using mice with human oral cancer, the researchers were next able to show that blocking CD36 completely prevented metastasis. In mice with cancer cells that had already metastasised, CD36 blocking antibodies led to the complete removal of metastases in 20% of the mice, whilst in the others it caused a dramatic reduction of 80-90% of metastases and reduced the size. Importantly, this was all achieved with no serious side effects.
The researchers are now developing new antibody-based therapeutics against CD36 that could potentially be suitable to treat a range of cancers in patients in the future.
Dr Lara Bennett, Science Communications Manager at Worldwide Cancer Research said: “We have been supporting Professor Benitah’s work for a number of years and it is fantastic to now see these truly game-changing results. If the team are able to go on to develop this antibody into a treatment for humans it could save thousands of lives every year.”
British laboratory autoclave manufacturer Priorclave has released a new How to Build video which takes the viewer on a journey through some of the key production, assembly and test procedures required for building an autoclave. It was filmed at the company’s UK manufacturing facility which produces some of the most advanced, energy-efficient, durable and reliable laboratory and research grade autoclave.
Each autoclave has three major parts; the pressure vessel, a frame and panels to support and enclose it plus wiring and controls.
The video starts where sheet and square-section steel is off-loaded and held in the metals store to await call-off into the metal fabrication workshop ready to start the manufacturing process. The journey though production includes a visit to a specialist welding section where that key component, the stainless-steel pressure, is manufactured. It is shown being creating using a unique seam welder developed by Priorclave so that they can produce ultra-smooth joins.
In the assembly area door and closure fittings are added to the pressure vessel so that it can be made water-tight ready for pressure testing. The final part of the video moves to the test centre where the autoclave is run; is function and safety tested against an extended checklist before being packed ready for despatch.
As a specialist in the design and manufacture of laboratory autoclaves Priorclave delivers its autoclaves around the world, each produced to satisfy individual customer demands in terms of functionality, operating environment and special installation requirements.
For those interested in how these first-class are built the video can be viewer here.
As a successful laboratory autoclave manufacturer Priorclave has developed more than 60 standards models which feature in its current range of benchtop, top and front loading, as well as double-door and power-door autoclaves. The company has also created an extensive range of ‘options and accessories to ensure that it can provide a perfect match to meet the customer sterilising requirements.
Just a spoonful of GalenIQ makes the medicine go down. Improve palatability of solid and liquid medicated candies with GalenIQ. The company can customising your formula with its long-established solution to bitter medicine: GalenIQ. For more information, click HERE.
Dr Gubala at the Medway School of Pharmacy (University of Kent) uses the Vitl Co-Mix for repeatable and efficient synthesis of nanoparticles
Kollicoat MAE 100-55 can directly replace comparable pH >5.5 enteric release materials in commercial formulations. For more click HERE.